ClinicalTrials.Veeva

Menu

Isotopic Imaging for Prodromal Alzheimer's Disease (ISALP)

C

Centre Hospitalier Universitaire de Nīmes

Status

Completed

Conditions

Alzheimer Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01231295
PHRC-N/2009/POK-01
2009-013476-53 (EudraCT Number)

Details and patient eligibility

About

The primary objective of this study is to characterize cerebral metabolism modifications using 18F-FDG PET technology and perfusion with 99MTC-ECD SPECT in patients with prodromal Alzheimer's Disease drawn from a high risk population. We also compare PET and SPECT imaging within this framework, and search for optimal diagnostic thresholds.

Enrollment

143 patients

Sex

All

Ages

70+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for the group with memory problems:

  • patient consulting for memory problems
  • caucasian
  • memory complaint is validated by a clinical evaluation
  • cognitive performance is sufficiently well preserved so that a diagnostic of dementia cannot be made (according to the DSM-IV-R and NINCDS-ADRDA criteria) at the time of inclusion
  • the patient speaks French
  • presence of an informant
  • accepts to sign consent

Inclusion Criteria for the group without memory problems (reference population):

  • at least four years of formal education
  • patient consulting for memory problems
  • memory problem reported by the patient is not validated by the consultation, nor by the battery of tests specified during screening
  • presence of an informant
  • Clinical Dementia Rating (CDR) = 0
  • accepts to sign consent

Exclusion Criteria:

  • Instrumental Activities of Daily Living (IADL): at least two items > 1
  • Anticholinesterasic treatments and/or memantin before study inclusion
  • major depressive syndrome, according to the Global Depressive Scale
  • Known neurodegenerative disease or general disease or major physical problems that could interfere with cognitive functioning and testing
  • Pathology that might lead to death in the short term (evolving cancer, non stable cardiopathy, hepatic, renal or respiratory insufficiency)
  • contra-indications for MRI, PET or SPECT scans
  • not affiliated with a social security regimen

Trial design

143 participants in 2 patient groups

Memory problems
Description:
Group with clinically validated memory problems
Reference group
Description:
Group without memory problems

Trial contacts and locations

25

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems